Melatonin prevents the free radical and MADD metabolic profiles induced by antituberculosis drugs in an animal model

Journal of Pineal Research

Volumn 38, Issue 2, 2005, Pages 100-106

  Loots, Du Toit ^a   Wiid, Ian J ^b,d   Page, Benedict J ^c   Mienie, Lodewyk J ^a   Van Helden, Paul D ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b Department of Medical Biochemistry   (South Africa)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Melatonin; Organic acids; Radicals; Rifater

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; CARBOXYLIC ACID; HYDROXYL RADICAL; MELATONIN; RIFATER; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME DEFECT; GAS CHROMATOGRAPHY; HORMONE ACTION; MASS SPECTROMETRY; METABOLIC DISORDER; METABOLIC PARAMETERS; NONHUMAN; RAT; RESPIRATORY CHAIN; URINALYSIS;

ANIMALS; ANTIOXIDANTS; ANTITUBERCULAR AGENTS; CARBOXYLIC ACIDS; DRUG COMBINATIONS; FREE RADICALS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HYDROXYBENZOIC ACIDS; ISONIAZID; MELATONIN; OXIDATIVE STRESS; PYRAZINAMIDE; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN;

EID: 14344260453     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2004.00176.x     Document Type: Article

References (58)

1. JASMER RM, SAUKKONEN JJ, BLUMBERG HM et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137:640-647.
2. STOUT JE, ENGEMANN JJ, CHENG AC et al. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003; 167:824-827.
3. POLOSA R, COLOMBRITA R, PROSPERINI G et al. A case of acute deterioration in asthma symptoms induced by isoniazid prophylaxis. Respir Med 1997; 91:438-440.
4. CAMERON SJ, CROMPTON GK. Severe hypoglycaemia in the course of treatment with streptomycin, isoniazid and ethionamide. Tubercle 1967; 48:307-310.
5. TAI DY, YEO JK, ENG PC et al. Intentional overdosage with isoniazid: case report and review of literature. Singapore Med J 1996; 37:222-225.
6. TEMMERMAN W, DHONDT A, VANDEWOUDE K. Acute isoniazid intoxication: seizures, acidosis and coma. Acta Clin Belg 1999; 54:211-216.
7. MARTINJAK-DVORSEK I, GORJUP V, HORVAT M et al. Acute isoniazid neurotoxicity during preventive therapy. Crit Care Med 2000; 28:567-568.
8. CHOUCHANE S, LIPPAI I, MAGLIOZZO RS. Catalase-peroxidase (Mycobacterium tuberculosis KatG) catalysis and isoniazid activation. Biochemistry 2000; 39:9975-9983.
9. BULATOVIC VM, WENGENACK NL, UHL JR et al. Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrob Agents Chemother 2002; 46:2765-2771.
10. KOHNO H, KUBO H, FURUKAWA K et al. Fluorometric determination of isoniazid and its metabolites in urine by high-performance liquid chromatography using in-line derivatization. Ther Drug Monit 1991; 13:428-432.
11. LAUTERBURG BH, SMITH CV, TODD EL et al. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 1985; 235:566-570.
12. DEGUCHI T, MASHIMO M, SUZUKI T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990; 265:12757-12760.
13. MORISAKJ N, KOBAYASHI H, IWASAKI S et al. Structure determination of ribosylated rifampicin and its derivative: new inactivated metabolites of rifampicin by mycobacterial strains. J Antibiot (Tokyo) 1995; 48:1299-1303.
14. LECAILLON JB, FEBVRE N, METAYER JP et al. Quantitative assay of rifampicin and three of its metabolites in human plasma, urine and saliva by high-performance liquid chromatography. J Chromatogr 1978; 145:319-324.
15. WARDELL WM, MCQUEEN EG. Urinary excretion of rifampicin and its metabolites as an index of rifampicin blood levels. N Z Med J 1970; 72:393-396.
16. KRAEMER HJ, FELTKAMP U, BREITHAUPT H. Quantification of pyrazinamide and its metabolites in plasma by ionic-pair high-performance liquid chromatography. Implications for the separation mechanism. J Chromatogr B Biomed Sci Appl 1998; 706:319-328.
17. MEHMEDAGIC A, VERITE P, MENAGER S et al. Determination of pyrazinamide and its main metabolites in rat urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 695:365-372.
18. NIEDERHOFER H, STAFFEN W, MAIR A et al. Brief report: melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Dev Disord 2003; 33:469-472.
19. LOOTS DT, MIENIE LJ, BERGH JJ et al. Acetyl-L-carnitine prevents total body hydroxyl free radical and uric acid production induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the rat. Life Sci 2004; 75:1243-1253.
20. CAMPO GM, AVENOSO A, CAMPO S et al. Aromatic trap analysis of free radicals production in experimental collagen-induced arthritis in the rat: protective effect of glycosaminoglycans treatment. Free Radic Res 2003; 37:257-268.
21. INGELMAN-SUNDBERG M, KAUR H, TERELIUS Y et al. Hydroxylation of salicylate by microsomal fractions and cytochrome P- 450. Lack of production of 2,3-dihydroxybenzoate unless hydroxyl radical formation is permitted. Biochem J 1991; 276 (Pt 3):753-757.
22. CHALMERS RA, LAWSON AM. Organic Acids in Man. Analytical Chemistry, Biochemistry and Diagnosis of the Organic Acidureas. Chapman and Hall, London, 1982; p. 523.
23. CHALMERS RA, HEALY MJ, LAWSON AM et al. Urinary organic acids in man. III. Quantitative ranges and patterns of excretion in a normal population. Clin Chem 1976; 22:1292-1298.
24. KNIGHT JA. Free radicals: their history and current status in aging and disease. Ann Clin Lab Sci 1998; 28:331-346.
25. KNIGHT JA. Diseases related to oxygen-derived free radicals. Ann Clin Lab Sci 1995; 25:111-121.
26. KWIATKOWSKA S, PIASECKA G, ZIEBA M et al. Increased serum concentrations of conjugated diens and malondialdehyde in patients with pulmonary tuberculosis. Respir Med 1999; 93:272-276.
27. WALUBO A, SMITH PJ, FOLB PI. Oxidative stress during antituberculous therapy in young and elderly patients. Biomed Environ Sci 1995; 8:106-113.
28. STRAUSZ J, MULLER-QUERNHEIM J, STEPPLING H et al. Oxygen radical production by alveolar macrophages in sarcoidosis in relation to activity status of bronchoalveolar lavage lymphocytes. Pneumologie 1990; 44 (Suppl. 1):222-223.
29. HOGG N. Free radicals in disease. Semin Reprod Endocrinol 1998; 16:241-248.
30. PARI L, KUMAR NA. Hepatoprotective activity of Moringa oleifera on antitubercular drug-induced liver damage in rats. J Med Food 2002; 5:171-177.
31. WALUBO A, SMITH P, FOLB PI. The role of oxygen free radicals in isoniazid-induced hepatotoxicity. Methods Find Exp Clin Pharmacol 1998; 20:649-655.
32. SODHI CP, RANA SV, MEHTA SK et al. Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug Chem Toxicol 1997; 20:255-269.
33. ATTRI S, RANA SV, VAIPHEI K et al. Isoniazid- and rifampicin-induced oxidative hepatic injury - protection by N-acetylcysteine. Hum Exp Toxicol 2000; 19:517-522.
34. HERMAN RP, WEBER MM. Site of action of isoniazid on the electron transport chain and its relationship to nicotinamide adenine dinucleotide regulation in Mycobacterium phlei. Antimicrob Agents Chemother 1980; 17:450-454.
35. JENNER P, DEXTER DT, SIAN J et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992; 32 Suppl.:S82-S87.
36. HALLIWELL B, GUTTERIDGE JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984; 219:1-14.
37. WIID I, SEAMAN T, HOAL EG et al. Total antioxidant levels are low during active TB and rise with anti-tuberculosis therapy. IUBMB Life 2004; 56:101-106.
38. ALLEGRA M, REITER RJ, TAN DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
39. REITER RJ, TAN DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 2003; 58:10-19.
40. REITER RJ. Antioxidant actions of melatonin. Adv Pharmacol 1997; 38:103-117.
41. REITER RJ, TAN D, OSUNA C et al. Actions of melatonin in the reduction of oxidative stress. A review (In Process Citation). J Biomed Sci 2000; 7:444-458.
42. POEGGELER B, SAARELA S, REITER RJ et al. Melatonin - a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci 1994; 738:419-420.
43. TAN DX, CHEN LD, POEGGELER B et al. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
44. BRZEZINSKI A. Melatonin in humans. N Engl J Med 1997; 336:186-195.
45. REITER RJ, TAN DX, SAINZ RM et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54:1299-1321.
46. WIID I, HOAL-VAN HELDEN E, HON D et al. Potentiation of isoniazid activity against Mycobacterium tuberculosis by melatonin. Antimicrob Agents Chemother 1999; 43:975-977.
47. RODRIGUEZ C, MAYO JC, SAINZ RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1-9.
48. ACUNA-CASTROVIE JOD, MARTIN M, MACIAS M et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001; 30:65-74.
49. YAMAGUCHI S, ORII T, SUZUKI Y et al. Newly identified forms of electron transfer flavoprotein deficiency in two patients with glutaric aciduria type II. Pediatr Res 1991; 29:60-63.
50. AMENDT BA, RHEAD WJ. The multiple acyl-coenzyme A dehydrpgenation disorders, glutaric aciduria type II and ethylmalonic-adipic aciduria. Mitochondrial fatty acid oxidation, acyl-coenzyme A dehydrogenase, and electron transfer flavoprotein activities in fibroblasts. J Clin Invest 1986; 78:205-213.
51. FRERMAN FE, GOODMAN SI. Deficiency of electron transfer flavoprotein or electron transfer flavoprotein: ubiquinone oxidoreductase in glutaric acidemia type II fibroblasts. Proc Natl Acad Sci U S A 1985; 82:4517-4520.
52. GOODMAN SI, BINARD RJ, WOONTNER MR et al. Glutaric acidemia type II: gene structure and mutations of the electron transfer flavoprotein: ubiquinone oxidoreductase (ETF:QO) gene. Mol Genet Metab 2002; 77:86-90.
53. GREGERSEN N, CHRISTENSEN MF, KOLVRAA S. Metabolic effects of carnitine medication in a patient with multiple acyl-CoA dehydrogenation deficiency. J Inherit Metab Dis 1985; 8 (Suppl. 2):139-140.
54. MANDEL H, AFRICK D, BLITZER M et al. The importance of recognizing secondary carnitine deficiency in organic acidaemias: case report in glutaric acidaemia type II. J Inherit Metab Dis 1988; 11:397-402.
55. VERJEE ZH, SHERWOOD WG. Multiple acyl-CoA dehydrogenase deficiency: a neonatal onset case responsive to treatment. J Inherit Metab Dis 1985; 8 (Suppl. 2):137-138.
56. KAUR J, SHARMA D, SINGH R. Acetyl-L-carnitine enhances Na(+), K(+)-ATPase glutathione-S-transferase and multiple unit activity and reduces lipid peroxidation and lipofuscin concentration in aged rat brain regions. Neurosci Lett 2001; 301:1-4.
57. SHARMAN EH, VAZIRI ND, NI Z et al. Reversal of biochemical and behavioural parameters of brain aging by melatonin and acetyl L-carnitine. Brain Res 2002; 957:223-230.
58. LEON J, ACUNA-CASTROVIE JOD, SAINZ RM et al. Melatonin and mitochondrial function. Life Sci 2004; 75:765-790.